Results 61 to 70 of about 591,464 (366)

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. [PDF]

, 2016
Rebound-associated vertebral fractures may follow treatment discontinuation of highly potent reversible bone antiresorptives, resulting from the synergy of rapid bone resorption and accelerated microdamage accumulation in trabecular bone ...
Popp, Albrecht, Zysset, Philippe, Lippuner, Kurt   +2 more
core   +1 more source

Generalized Discontinuity [PDF]

, 2012
We define and study a calculus of discontinuity, a version of displacement calculus, which is a logic of segmented strings in exactly the same sense that the Lambek calculus is a logic of strings. Like the Lambek calculus, the displacement calculus is a sequence logic free of structural rules, and enjoys Cut-elimination and its corollaries: the ...
Glyn Morrill, Oriol Valentín
openaire   +1 more source

Representation of Older Adult Patients in Clinical Trials

Clinical and Translational Science
Older adults remain significantly underrepresented in clinical trials. This is concerning because age‐associated physiological changes can alter drug pharmacokinetics and pharmacodynamics.
Sebastian Haertter, Navita L. Mallalieu, Soundos Saleh, Paul Goldsmith, Rucha Sane, Jack Cook   +5 more
doaj   +1 more source

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer, 2019
After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with ...
F. Palandri, M. Breccia, M. Bonifacio, N. Polverelli, E. Elli, G. Benevolo, M. Tiribelli, E. Abruzzese, A. Iurlo, F. Heidel, M. Bergamaschi, A. Tieghi, M. Crugnola, F. Cavazzini, G. Binotto, A. Isidori, N. Sgherza, C. Bosi, B. Martino, R. Latagliata, G. Auteri, L. Scaffidi, D. Griguolo, M. Trawinska, D. Cattaneo, L. Catani, M. Krampera, R. Lemoli, A. Cuneo, G. Semenzato, R. Foà, F. Di Raimondo, D. Bartoletti, M. Cavo, G. Palumbo, N. Vianelli   +35 more
semanticscholar   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: A qualitative interview study

Health Expectations
Background Our knowledge of the broader impacts of antidepressant withdrawal, beyond physical side effects, is limited. Further research is needed to investigate the lived experiences of withdrawal, to aid clinicians on how to guide patients through the ...
Raqeeb Mahmood, Vuokko Wallace, Professor Nicola Wiles, Professor David Kessler, Katherine S. Button, Graeme Fairchild   +5 more
doaj   +1 more source

Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors

Patient Preference and Adherence, 2022
Tracy J Sims,1 Kristina S Boye,1 Susan Robinson,2 Tessa Kennedy-Martin2 1Eli Lilly and Company, Indianapolis, IN, USA; 2KMHO Ltd, Brighton, UKCorrespondence: Tracy J Sims, Eli Lilly and Company, Indianapolis, IN, USA, Tel +1-317-403-1219, Email ...
Sims TJ, Boye KS, Robinson S, Kennedy-Martin T   +3 more
doaj  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Reasons for early discontinuation.

, 2022
Reasons for early discontinuation.
Dániel Sandi (6252581), Attila Csányi (12446837), Enikő Dobos (12191539), Krisztina Bencsik (6252584), László Vécsei (336072), Judit Füvesi (12191521), Zsanett Fricska-Nagy (12191518), Krisztina Kovács (238775), László Horváth (12446834), Péter Ács (12446828), Botond Cseh (12197708), Zsuzsanna Nagy (64689), Tünde Csépány (10272518), Csilla Rózsa (12446831), Tamás Biernacki (12191524), Tamás Zsigmond Kincses (3130233)   +15 more
core   +1 more source